Earnings call transcript: Medicure Q4 2025 revenue climbs, stock drops

Medicure posted Q4 2025 net revenue of CAD 8.5 million, up 44.07% year over year, but full-year net loss widened sharply to CAD 7.1 million from CAD 1.0 million, driven by a CAD 2.1 million CMS rebate liability, higher pharmacy costs, and ongoing R&D spending. Shares fell 33.33% to $0.45, near the 52-week low of $0.83, as investors focused on declining cash of CAD 3.8 million and pressure in AGGRASTAT from generic competition. Offsetting positives include growth in Marley Drug and continued MC-1 phase III development, but near-term sentiment remains weak.

Analysis

The market is treating this as a balance-sheet-and-cash-flow story, not a revenue story, and that’s likely the right lens. The core issue is that Medicure is shifting from a legacy product company with optionality to a more capex-intensive hybrid model: pharmacy roll-up plus R&D burn, with working capital tied up in lower-quality earnings. That combination tends to compress multiples fast because every incremental dollar of growth now comes with a larger probability of dilution or a reset in capital allocation.

Second-order, the pharmacy acquisitions may be strategically sound but they also import lower-margin revenue and integration risk right when the company’s equity currency is impaired. If management can extract purchasing power and cross-sell ZYPITAMAG, gross margin could inflect over the next 2-3 quarters, but the market will demand proof in cash conversion, not promises. Until then, any upside from acquisition synergies is likely offset by investor concern that the pharmacy platform is being used to mask deterioration in the legacy franchise.

The near-term catalyst set is asymmetric: a resolution of the CMS dispute, evidence that pharmacy margins are expanding, or a non-dilutive financing event tied to MC-1 could spark a sharp relief rally because the stock is already priced for distress. The flip side is that if cash burn remains elevated, the company is within a 2-4 quarter window where financing risk becomes the dominant variable. That makes the equity vulnerable to further downside on even modest operational misses, especially if the market concludes that R&D is a long-dated option rather than a value driver.

The contrarian view is that the selloff may have over-penalized the strategic assets, particularly the direct-to-patient channel and the MC-1 voucher optionality. But that optionality only matters if the company can fund it without punitive dilution. In other words, this is less a debate about whether the assets have value and more about who captures that value: current holders or a future recapitalization cycle.

Key Decisions for Investors

• Avoid initiating a fresh long in MCUJF/MPH for now; wait 1-2 quarters for evidence of cash burn stabilization and pharmacy gross-margin expansion. Risk/reward is poor until the market sees operating leverage, because downside from financing risk likely exceeds upside from a normal beat.
• For existing holders, consider selling covered calls into any post-earnings bounce over the next 30-60 days to monetize volatility while the stock digests distress risk. This is attractive if the name remains range-bound near liquidation-value optics.
• Pair trade: long a profitable pharmacy-chain or PBM beneficiary vs short MCUJF/MPH if you want exposure to the direct-to-patient theme without balance-sheet risk. The short leg benefits if the market continues to discount pharmacy roll-up economics in microcaps.
• Set an alert around the next CMS-appeal milestone and any disclosure on recovered cash; that is the most plausible 3-6 month catalyst for a 20-40% squeeze. If no recovery is announced, expect the equity to trade more like an external financing story than a fundamentals story.
• Speculative only: small-sized call options or warrants exposure tied to MC-1 approval/voucher optionality if available, funded by a short in the common. This isolates the long-dated biotech upside while neutralizing the near-term burn and dilution overhang.